New transgenic models of Parkinson's disease using genome editing technology. / Nuevos modelos transgénicos para el estudio de la enfermedad de Parkinson basados en sistemas de edición con nucleasas.
Neurologia (Engl Ed)
; 35(7): 486-499, 2020 Sep.
Article
en En, Es
| MEDLINE
| ID: mdl-29196142
ABSTRACT
INTRODUCTION:
Parkinson's disease (PD) is the second most common neurodegenerative disorder. It is characterised by selective loss of dopaminergic neurons in the substantia nigra pars compacta, which results in dopamine depletion, leading to a number of motor and non-motor symptoms. DEVELOPMENT In recent years, the development of new animal models using nuclease-based genome-editing technology (ZFN, TALEN, and CRISPR/Cas9 nucleases) has enabled the introduction of custom-made modifications into the genome to replicate key features of PD, leading to significant advances in our understanding of the pathophysiology of the disease.CONCLUSIONS:
We review the most recent studies on this new generation of in vitro and in vivo PD models, which replicate the most relevant symptoms of the disease and enable better understanding of the aetiology and mechanisms of PD. This may be helpful in the future development of effective treatments to halt or slow disease progression.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Animales Modificados Genéticamente
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
/
Es
Revista:
Neurologia (Engl Ed)
Año:
2020
Tipo del documento:
Article